BioNexus Q3: Revenue Down 97.9%, Going Concern Doubt Reiterated, 560K Shares Issued for RYET Deal
BGLC is trading near its 52-week low of $0.621 (9.5% above the low).
Summary
BioNexus posted a 97.9% revenue collapse and a $1.88M nine-month loss while reiterating going concern doubt, and disclosed 560,000 new shares issued to close the RYET CogniAI license in November.
Key Events · Earnings and Guidance · BGLC
-
Revenue Collapses 97.9%
Nine-month revenue fell to $146,915 from $6,941,151, with Chemrex trading down 97.91% and MRNA Scientific recording zero Q3 revenue.
-
Going Concern Doubt Reiterated
A net loss of $1,884,406 and operating cash burn of $827,627 left an accumulated deficit of $8,311,633; management says its ATM-dependent plans do not alleviate substantial doubt.
-
560,000 Shares Issued for RYET
On November 13, 2026 the company issued 410,000 shares for the stated $3.5M CogniAI license and 150,000 shares for 500,000 RYET shares, lifting shares outstanding to 3,493,442.
-
Insider Stock Awards of $799,998
516,128 fully vested shares were issued August 13, 2026 at $1.55 fair value, including 338,709 to the CEO and 96,774 to the CFO.
Analysis · BGLC · Industrial Applications And Services
Revenue has all but evaporated: $146,915 for the nine months versus $6,941,151 a year ago, as Chemrex's chemical trading collapsed following former management's alleged unauthorized payments and the MRNA lab went dark pending the VitaGuard relocation. The company lost $1,884,406 over the nine months and carries an $8.3 million accumulated deficit, and management explicitly states its plans do not alleviate substantial doubt about surviving the next twelve months. Even so, it keeps paying for licenses in stock: 516,128 shares to insiders in August and 560,000 shares to RYET in November, pushing shares outstanding from 2,417,314 at year-end to 3,493,442 today. The one bright spot is that the Chemrex material weakness is now reported as remediated.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BGLC was trading at $0.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.62 to $4.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.